KLOW blend (GHK-Cu + BPC-157 + TB-500 + KPV)
KLOW is the GLOW blend with a fourth peptide, KPV, added. The usual vial has a fixed ratio that is mostly GHK-Cu by weight. The mixture has never been tested in people, and a mixed vial falls outside the 2026 compounding policy.
- Legal lane: outside the October 2026 policy, which allows one active ingredient per product. Not FDA-approved.
- Evidence grade: D for the combination
- What is in it: GHK-Cu, BPC-157, TB-500 and KPV. The most common vial is 80 mg: 50 mg GHK-Cu and 10 mg each of the other three.
- Established human dose: none
What it is
The GLOW blend (GHK-Cu, BPC-157 and TB-500) with the anti-inflammatory peptide KPV added. Some compounders add a fifth peptide, larazotide, which has been studied for intestinal permeability.
Because the ratio is fixed in the vial, you cannot adjust one ingredient without moving all four. KLOW is 62.5% GHK-Cu by weight. If the ingredient you want is BPC-157, you are buying mostly something else.
What the evidence shows
There is no trial of this blend, and no study has shown that the combination does better than its ingredients taken separately.
The evidence that exists applies to each ingredient on its own. For BPC-157 and TB-500 it is almost entirely animal work. Each ingredient's page has its grade and what has been shown.
Legal status
In October 2026, HHS issued an interim policy allowing licensed pharmacies to compound six peptides on prescription: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. One condition is that the compounded product contains a single active ingredient from that list. Law firms that analyzed the policy concluded that products with more than one active ingredient fall outside it.
Three of KLOW's four ingredients are on that list, which is why 2026 looked like the year blends became legitimate. The single-ingredient condition means the mixed vial is still outside the policy, and GHK-Cu is not one of the six. A seller offering KLOW is working outside the policy or is not a licensed compounding pharmacy.
Reported dosing
No dose has been established for this blend.
No human trial has tested it. The mixing tables and schedules published by sellers are their own arithmetic applied to a product nobody has studied. Where we can report dosing for an individual ingredient, it is on that compound's own page, with the source shown.
Safety
- You cannot tell what worked. If you improve, you have learned nothing about which ingredient to keep.
- You cannot tell what went wrong. A reaction means stopping everything, with no way to find the cause except starting over one at a time.
- The mixture itself is unstudied. Reviews of compounded multi-peptide preparations note that no safety or absorption work exists on the combinations.
- Quality is a separate risk. A pharmacy following the policy closely will not make a blend, so the product comes from outside that system.
Copper accumulates. Most of a KLOW vial is GHK-Cu, which delivers copper with every dose. Long courses are a reason to pay attention to copper and zinc balance, which is a conversation for a clinician.
If you are considering it anyway
- Ask the seller which pharmacy compounded it and whether that pharmacy is operating under the HHS policy. A blend cannot be, and a straight answer tells you what you are dealing with.
- Ask for a certificate of analysis showing each ingredient's identity and purity separately, not one figure for the vial.
- Consider one compound at a time. It is slower, and it is the only way to learn how you respond.
- If a clinician is prescribing, ask why a blend and not separate vials, and whether the ratio can be adjusted for you.
Common questions
What is in KLOW?
GHK-Cu, BPC-157, TB-500 and KPV. The most common vial holds 50 mg of GHK-Cu and 10 mg of each of the others.
What is the difference between GLOW and KLOW?
KLOW is the GLOW formula with KPV added as a fourth peptide.
Is KLOW legal?
Not under the October 2026 policy, which allows one active ingredient per compounded product.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.
Sources
- HHS: 503A peptide enforcement discretion policy, including the single-ingredient condition
- McDermott Will & Emery: the conditions exclude multiple-ingredient compounded products
- Buchanan Ingersoll & Rooney: single-active-ingredient formulations under the policy
- Healio: advisory committee discussion, including the combination-use concern raised on TB-500
All three repair blends are compared on blends and stacks. To keep a private record of what you take, use the dose and progress log.